Sensus Healthcare Inc
$ 3.84
0.52%
24 Feb - close price
- Market Cap 63,226,000 USD
- Current Price $ 3.84
- High / Low $ 3.89 / 3.75
- Stock P/E N/A
- Book Value 1.57
- EPS -0.47
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.15 %
- 52 Week High 5.92
- 52 Week Low 3.03
About
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Analyst Target Price
$6.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-14 | 2025-08-07 | 2025-05-15 | 2025-02-05 | 2024-11-14 | 2024-08-08 | 2024-05-09 | 2024-02-08 | 2023-11-09 | 2023-08-03 | 2023-05-03 |
| Reported EPS | -0.19 | -0.06 | -0.06 | -0.16 | 0.09 | 0.07 | 0.1 | 0.14 | 0.26 | -0.09 | -0.02 | -0.12 |
| Estimated EPS | -0.04 | -0.08 | 0.01 | 0.02 | 0.12 | -0.01 | 0.02 | -0.05 | 0.12 | -0.02 | -0.08 | 0.13 |
| Surprise | -0.15 | 0.02 | -0.07 | -0.18 | -0.03 | 0.08 | 0.08 | 0.19 | 0.14 | -0.07 | 0.06 | -0.25 |
| Surprise Percentage | -375% | 25% | -700% | -900% | -25% | 800% | 400% | 380% | 116.6667% | -350% | 75% | -192.3077% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.0567 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRTS
2026-02-18 18:27:18
Sensus Healthcare, Inc. has introduced Sensus Healthcare Financial Services to simplify the acquisition of its superficial radiotherapy (SRT) systems for dermatology practices. This program offers flexible financing options to reduce administrative and financial barriers, complementing the company's commercial strategy. The initiative comes after recent reimbursement clarity and despite Sensus Healthcare reporting Q4 2025 earnings and revenue below expectations.
2026-02-18 13:27:48
Sensus Healthcare has launched Sensus Healthcare Financial Services to simplify the acquisition of its superficial radiotherapy (SRT) systems for dermatology practices. This initiative aims to remove financial barriers, offering flexible purchase and lease options, particularly relevant given recent positive changes in reimbursement codes. The move comes as Sensus Healthcare tries to improve its financial standing after reporting fourth-quarter 2025 results that missed analyst expectations.
2026-02-18 13:27:48
Sensus Healthcare, Inc. has introduced "Sensus Healthcare Financial Services" to simplify the acquisition of its superficial radiotherapy (SRT) systems for dermatology practices. This program offers streamlined processes and flexible financing options, including fair market value leasing, aiming to improve customer conversion as new reimbursement clarity enhances financial visibility for SRT treatments. It specifically targets reducing administrative and financial barriers, strengthening customer relationships, and supporting the company's growth strategy.
2026-02-15 12:27:24
Sensus Healthcare (NASDAQ:SRTS) recently reported its annual results, showing an 11% shortfall in revenues compared to analyst estimates and larger-than-expected statutory losses. Following these results, analysts have significantly cut their revenue outlook for 2026 and expect increased losses per share, leading to a 33% reduction in the average price target. Despite these downgrades, the company is still forecast to grow its revenue faster than the medical equipment industry average.
2026-02-14 17:27:48
Sensus Healthcare (SRTS) is forecasting a rebound in profitability and revenue in 2026, despite a challenging 2025 marked by significant declines. This optimism is driven by new CPT codes for superficial and image-guided SRT effective January 2026, which are expected to boost reimbursements. The company also highlights its strong balance sheet, international growth, and expanding FDA fair deal program as key drivers for future success.
2026-02-13 23:57:24
Sensus Healthcare's Q4 earnings call revealed a challenging 2025 with significant revenue declines and a swing to losses, primarily due to a key lost customer. However, management expressed optimism for a turnaround in 2026, driven by new CPT codes for superficial and image-guided SRT expected to boost reimbursements by 300%. The company plans to scale commercial efforts and expand internationally, leveraging its strong balance sheet to navigate the transition.
